Vera Therapeutics (NASDAQ: VERA) reports Chief Legal Officer to step down

Rhea-AI Filing Summary

Vera Therapeutics, Inc. reported a leadership change, stating that Jason Carter will no longer serve as the company’s Chief Legal Officer, effective December 24, 2025. The change was disclosed as an officer departure under a current report, with no additional details provided about his future role or any replacement.

false 0001831828 0001831828 2025-12-16 2025-12-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 16, 2025

Vera Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware		001-40407		81-2744449
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

2000 Sierra Point Parkway, Suite 1200		94005
Brisbane, California
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: (650) 770-0077

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A common stock, $0.001 par value per share		VERA		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 16, 2025, Vera Therapeutics, Inc. (the “Company”) announced that Jason Carter will no longer serve as the Company’s Chief Legal Officer, effective as of December 24, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Vera Therapeutics, Inc.
Date: December 17, 2025				By:		/s/ Marshall Fordyce, M.D.
						Marshall Fordyce, M.D. Chief Executive Officer

FAQ

What leadership change did Vera Therapeutics (VERA) disclose in this SEC filing?

Vera Therapeutics disclosed that Jason Carter will no longer serve as the company’s Chief Legal Officer, effective December 24, 2025.

When will Jason Carter’s role as Chief Legal Officer at Vera Therapeutics (VERA) end?

Jason Carter’s role as Chief Legal Officer will end effective December 24, 2025, according to the company’s current report.

Which executive position is affected by the change reported by Vera Therapeutics (VERA)?

The change affects the position of Chief Legal Officer at Vera Therapeutics, previously held by Jason Carter.

Does the filing state who signed the report for Vera Therapeutics (VERA)?

Yes. The report was signed on behalf of Vera Therapeutics by Marshall Fordyce, M.D., the company’s Chief Executive Officer.

On what date did Vera Therapeutics (VERA) announce the Chief Legal Officer change?

The company announced the change on December 16, 2025, stating that Jason Carter will no longer serve as Chief Legal Officer effective December 24, 2025.